How an Obesity Drug Could Help Alcohol Use Disorder
Promising preclinical and early clinical data suggest a role for GLP-1 receptor agonist therapy in treating alcohol use disorder.
Stay updated with breaking news from Alcohol Reduction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Promising preclinical and early clinical data suggest a role for GLP-1 receptor agonist therapy in treating alcohol use disorder.
Wegovy and Ozempic, drugs commonly used for weight loss, may be used to treat alcohol addiction, researchers say. Studies on semaglutide, the ingredient in both drugs, are examining whether people who take the medication can reduce alcohol consumption and cravings to drink. One newly published study offers the first evidence that GLP-1 agonists can help people manage alcohol addiction.
<p>The first published evidence from humans that semaglutide specifically reduces the symptoms of Alcohol Use Disorder (AUD) has been published in <em>The Journal of Clinical Psychiatry.</em></p>
A research team from the University of Oklahoma and Oklahoma State University says it has published the first evidence that the drug semaglutide specifically reduces symptoms of alcohol use disorder.
Anecdotal reports first surfaced last summer that the obesity 'wonder' drug - taken as a daily pill or injection - was curbing the taste for alcohol among those prescribed it for weight loss .